FI3774745T3 - Oksatsoliyhdistekide - Google Patents
Oksatsoliyhdistekide Download PDFInfo
- Publication number
- FI3774745T3 FI3774745T3 FIEP19718465.8T FI19718465T FI3774745T3 FI 3774745 T3 FI3774745 T3 FI 3774745T3 FI 19718465 T FI19718465 T FI 19718465T FI 3774745 T3 FI3774745 T3 FI 3774745T3
- Authority
- FI
- Finland
- Prior art keywords
- crystal
- infrared absorption
- measured
- peaks
- rays
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims 14
- -1 Oxazole compound Chemical class 0.000 title claims 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 claims 2
- 238000000862 absorption spectrum Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018072717 | 2018-04-04 | ||
| PCT/JP2019/014730 WO2019194211A1 (en) | 2018-04-04 | 2019-04-03 | Oxazole compound crystal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3774745T3 true FI3774745T3 (fi) | 2024-06-19 |
Family
ID=66223774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19718465.8T FI3774745T3 (fi) | 2018-04-04 | 2019-04-03 | Oksatsoliyhdistekide |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US11414391B2 (enExample) |
| EP (2) | EP4400167A3 (enExample) |
| JP (4) | JP7326295B2 (enExample) |
| KR (2) | KR102764726B1 (enExample) |
| CN (1) | CN111902402A (enExample) |
| AU (2) | AU2019249562B2 (enExample) |
| BR (1) | BR112020019377A2 (enExample) |
| CA (1) | CA3095866A1 (enExample) |
| DK (1) | DK3774745T3 (enExample) |
| EA (1) | EA202092393A1 (enExample) |
| ES (1) | ES2982586T3 (enExample) |
| FI (1) | FI3774745T3 (enExample) |
| HR (1) | HRP20240858T1 (enExample) |
| HU (1) | HUE066793T2 (enExample) |
| IL (2) | IL277730B2 (enExample) |
| LT (1) | LT3774745T (enExample) |
| MX (1) | MX2020010435A (enExample) |
| MY (1) | MY202406A (enExample) |
| PH (1) | PH12020551605A1 (enExample) |
| PL (1) | PL3774745T3 (enExample) |
| PT (1) | PT3774745T (enExample) |
| SG (1) | SG11202009564TA (enExample) |
| SI (1) | SI3774745T1 (enExample) |
| TW (2) | TWI860993B (enExample) |
| WO (1) | WO2019194211A1 (enExample) |
| ZA (1) | ZA202006134B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3774745T3 (da) * | 2018-04-04 | 2024-06-17 | Otsuka Pharma Co Ltd | Krystal af en oxazolforbindelse |
| EP4501324A1 (en) | 2022-03-25 | 2025-02-05 | Otsuka Pharmaceutical Co., Ltd. | Wound treatment composition |
| CN115887463A (zh) * | 2022-12-27 | 2023-04-04 | 瑞石生物医药有限公司 | 一种含环酰胺化合物的药物组合物 |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI330639B (en) * | 2005-11-15 | 2010-09-21 | Otsuka Pharma Co Ltd | Oxazole compound and pharmaceutical composition |
| WO2014034958A1 (en) * | 2012-08-30 | 2014-03-06 | Otsuka Pharmaceutical Co., Ltd. | Method for producing oxazole compound |
| TWI726027B (zh) | 2015-12-28 | 2021-05-01 | 日商大塚製藥股份有限公司 | 軟膏 |
| DK3774745T3 (da) * | 2018-04-04 | 2024-06-17 | Otsuka Pharma Co Ltd | Krystal af en oxazolforbindelse |
-
2019
- 2019-04-03 DK DK19718465.8T patent/DK3774745T3/da active
- 2019-04-03 SI SI201930776T patent/SI3774745T1/sl unknown
- 2019-04-03 PL PL19718465.8T patent/PL3774745T3/pl unknown
- 2019-04-03 KR KR1020207031251A patent/KR102764726B1/ko active Active
- 2019-04-03 CN CN201980022064.2A patent/CN111902402A/zh active Pending
- 2019-04-03 EP EP24172132.3A patent/EP4400167A3/en active Pending
- 2019-04-03 ES ES19718465T patent/ES2982586T3/es active Active
- 2019-04-03 IL IL277730A patent/IL277730B2/en unknown
- 2019-04-03 JP JP2020539109A patent/JP7326295B2/ja active Active
- 2019-04-03 CA CA3095866A patent/CA3095866A1/en active Pending
- 2019-04-03 SG SG11202009564TA patent/SG11202009564TA/en unknown
- 2019-04-03 IL IL315425A patent/IL315425A/en unknown
- 2019-04-03 TW TW108111946A patent/TWI860993B/zh active
- 2019-04-03 US US17/044,892 patent/US11414391B2/en active Active
- 2019-04-03 EP EP19718465.8A patent/EP3774745B1/en active Active
- 2019-04-03 LT LTEPPCT/JP2019/014730T patent/LT3774745T/lt unknown
- 2019-04-03 MY MYPI2020005118A patent/MY202406A/en unknown
- 2019-04-03 PT PT197184658T patent/PT3774745T/pt unknown
- 2019-04-03 TW TW113146840A patent/TW202515853A/zh unknown
- 2019-04-03 KR KR1020257003493A patent/KR20250022254A/ko active Pending
- 2019-04-03 FI FIEP19718465.8T patent/FI3774745T3/fi active
- 2019-04-03 WO PCT/JP2019/014730 patent/WO2019194211A1/en not_active Ceased
- 2019-04-03 AU AU2019249562A patent/AU2019249562B2/en active Active
- 2019-04-03 EA EA202092393A patent/EA202092393A1/ru unknown
- 2019-04-03 MX MX2020010435A patent/MX2020010435A/es unknown
- 2019-04-03 HU HUE19718465A patent/HUE066793T2/hu unknown
- 2019-04-03 BR BR112020019377-1A patent/BR112020019377A2/pt unknown
- 2019-04-03 HR HRP20240858TT patent/HRP20240858T1/hr unknown
-
2020
- 2020-09-30 PH PH12020551605A patent/PH12020551605A1/en unknown
- 2020-10-02 ZA ZA2020/06134A patent/ZA202006134B/en unknown
-
2021
- 2021-12-03 JP JP2021196978A patent/JP2022037040A/ja active Pending
-
2022
- 2022-07-07 US US17/859,675 patent/US11840512B2/en active Active
-
2023
- 2023-10-03 JP JP2023171778A patent/JP2024001115A/ja active Pending
- 2023-10-31 US US18/498,894 patent/US20240076275A1/en not_active Abandoned
-
2024
- 2024-09-24 AU AU2024220015A patent/AU2024220015A1/en active Pending
-
2025
- 2025-03-27 US US19/092,743 patent/US20250250243A1/en active Pending
- 2025-06-04 JP JP2025093100A patent/JP2025128238A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3774745T3 (fi) | Oksatsoliyhdistekide | |
| HRP20210507T1 (hr) | Supstituirani 5-fluoro-1h-pirazolopiridini u kristalnom obliku | |
| MX373612B (es) | Cristal del compuesto alquinil benceno 3,5-disustituido. | |
| BR112022018600A2 (pt) | Compostos, composição farmacêutica, método de tratamento de uma doença e combinação | |
| EA200802119A1 (ru) | Новая кристаллическая форма vi агомелатина, способ его получения и фармацевтические композиции, которые ее содержат | |
| WO2015130842A3 (en) | Ether compounds for treatment of complement mediated disorders | |
| EA201690153A1 (ru) | Замещенные бензофуранильные и бензоксазолильные соединения и их применения | |
| HRP20211670T1 (hr) | Derivat difenilmetana u kristalnom obliku | |
| HRP20211834T1 (hr) | Kristalni čvrsti oblici 6-karboksi-2-(3,5-diklorfenil)benzoksazola | |
| HK1215579A1 (zh) | 被取代的2，3-二氫苯並呋喃基化合物和其用途 | |
| RU2016137668A (ru) | Новые производные каннабидиол-хинона | |
| CY1110647T1 (el) | Παραγωγα ν-(ετεροαρυλ)-1η-ινδολο-2-καρβοξαμιδιων και η χρηση τους ως δεσμοι του βανιλλοειδους υποδοχεα trpv1 | |
| WO2014136282A8 (en) | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient | |
| WO2016164763A8 (en) | Compositions and methods for treating cns disorders | |
| EA200601271A1 (ru) | Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
| RU2017141763A (ru) | Кристалл (6S,9aS)-N-бензил-8-({ 6-[3-(4-этилпиперазин-1-ил)азетидин-1-ил]пиридин-2-ил} метил)-6-(2-фтор-4-гидроксибензил)-4,7-диоксо-2-(проп-2-ен-1-ил)гексагидро-2H-пиразино[2,1-c][1,2,4]триазин-1(6H)-карбоксамида | |
| EA200601274A1 (ru) | Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
| JP2022037040A5 (enExample) | ||
| WO2015042414A8 (en) | Multicyclic compounds and methods of using same | |
| WO2014164648A4 (en) | Solid state forms of a quinazoline derivative and its use as a braf inhibitor | |
| WO2019207257A8 (fr) | Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices | |
| PH12019502588A1 (en) | Crystal form c of sanzuohuangcaotong, preparation method and use thereof | |
| EA201892566A1 (ru) | Кристаллический полиморф 15в-гидрокси-осатерона ацетата | |
| JP2021517111A5 (enExample) | ||
| WO2020132471A8 (en) | Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof |